Hepatocellular Carcinoma

WASHINGTON — Fewer Black and Hispanic patients received curative treatment for early-stage hepatocellular carcinoma compared with white patients, according to research presented at The Liver Meeting.

WASHINGTON — The MELD score at transplant minus three points policy led to poor survival and recurrence outcomes after liver transplantation among patients with hepatocellular carcinoma, according to research at The Liver Meeting.

The FDA granted orphan drug designation to OTX-2002 for the treatment of hepatocellular carcinoma, according to the agent’s manufacturer.

Second- and third-generation individuals of Mexican descent who reside in the U.S. had a higher risk for developing hepatocellular carcinoma than first-generation U.S. Mexicans, according to study results.

Investigators have identified an elevated risk for hepatocellular carcinoma in people exposed to per- and polyfluoroalkyl substances, according to a study published in JHEP Reports.

Despite increased perioperative risks in older patients with hepatocellular carcinoma and cirrhosis, orthotropic liver transplantation provides greater survival benefit compared with ablative therapies, according to new research.

Internally validated nomograms predicted the probability of early death and identified risk factors among patients with advanced hepatocellular carcinoma, according to research published in BMC Gastroenterology.

Researchers reported excellent 10-year outcomes among patients with hepatocellular carcinoma that was downstaged to within Milan criteria prior to liver transplant, according to a multicenter analysis published in JAMA Surgery.

A combination of viruses has been linked to an unexplained surge of severe hepatitis in children.

A phase 3 trial of the PD-1 inhibitor tislelizumab met its primary endpoint of noninferior OS compared with sorafenib as first-line treatment for adults with unresectable hepatocellular carcinoma, according to the agent’s manufacturer.